BOSTON–(BUSINESS WIRE)–AcuityMD, providers of a novel commercial platform for medical technology (MedTech) companies, announces its partnership with FEMSelect, a MedTech manufacturer specializing in a minimally invasive approach to treat pelvic floor disorders (PFD). FEMSelect is leveraging AcuityMD’s platform to accelerate identification…
DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers…
The regulatory environment for medical devices is in a transitional period. With the increased focus on patient safety, the MDR has introduced many changes to the requirements and processes involved. Designed for professionals with a working knowledge of medical device…
Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results. “Bausch + Lomb…
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 “During the first quarter, LivaNova delivered solid revenue growth,” said…
the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a study “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on…
Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis will be presented at the upcoming EuroPCR 2023 Conference. EuroPCR…
Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the second quarter of fiscal year 2023. 2QFY23 Summary “We are pleased to report results for the second quarter that exceeded the high-end of our guidance. Demand for…
A leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2023 financial results. “We had an extraordinary start to 2023 driven by strength across our…
The ultrafast polymer 3D printing leader, announced today at Rapid + TCT 2023 the immediate availability of its XiP Pro ultrafast industrial 3D printer, providing the highest daily production throughput and lowest total cost of ownership in its class. Featuring print speeds…
a privately held company dedicated to developing bio-engineered surgical implants for connective tissue restoration, today announced initiation of the Bridge Registry Post-Market Study of the company’s Bridge-Enhanced ACL Restoration (BEAR®) Implant for anterior cruciate ligament (ACL) tears. “I look forward…
Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced that data from its BIOADAPTOR RCT randomized controlled trial (RCT), an international, multicenter, single-blind study enrolling 445 patients will be presented at the EuroPCR conference in Paris. The data compare…